Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment.
Ianza A, Giudici F, Pinello C, Corona SP, Strina C, Bernocchi O, Bortul M, Milani M, Sirico M, Allevi G, Aguggini S, Cocconi A, Azzini C, Dester M, Cervoni V, Bottini A, Cappelletti M, Generali D. Ianza A, et al. Among authors: cervoni v. Tumour Biol. 2020 Jun;42(6):1010428320925301. doi: 10.1177/1010428320925301. Tumour Biol. 2020. PMID: 32489146 Free article. Clinical Trial.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Sirico M, et al. Among authors: cervoni v. Cancers (Basel). 2020 Nov 10;12(11):3314. doi: 10.3390/cancers12113314. Cancers (Basel). 2020. PMID: 33182575 Free PMC article.
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V, Macchiavelli A, Roviello G, Generali D. Bernocchi O, et al. Among authors: cervoni v. Pharmaceuticals (Basel). 2021 Feb 16;14(2):159. doi: 10.3390/ph14020159. Pharmaceuticals (Basel). 2021. PMID: 33669326 Free PMC article.
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D. Schettini F, et al. Among authors: cervoni v. Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776. eCollection 2021. Front Oncol. 2021. PMID: 34262869 Free PMC article.
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Corona SP, et al. Among authors: cervoni v. Oncotarget. 2020 Jun 9;11(23):2172-2181. doi: 10.18632/oncotarget.27612. eCollection 2020 Jun 9. Oncotarget. 2020. PMID: 32577163 Free PMC article.
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients.
Generali D, Rocca A, Strina C, Milani M, Fiorino E, Cervoni V, Azzini C, Saracino A, Ciliberto I, Ziglioli N, Alberio M, Giudici F, Dester M, Ciani O, Fornaro G, Aguggini S, Dreezen C, Pronin D, Ende S. Generali D, et al. Among authors: cervoni v. Heliyon. 2024 Oct 26;10(21):e39485. doi: 10.1016/j.heliyon.2024.e39485. eCollection 2024 Nov 15. Heliyon. 2024. PMID: 39553665 Free PMC article.
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Schettini F, De Bonis MV, Strina C, Milani M, Ziglioli N, Aguggini S, Ciliberto I, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Ferrero G, Ungari M, Locci M, Paris I, Scambia G, Ruocco G, Generali D. Schettini F, et al. Among authors: cervoni v. Sci Rep. 2023 Jul 24;13(1):11951. doi: 10.1038/s41598-023-38760-z. Sci Rep. 2023. PMID: 37488154 Free PMC article. Clinical Trial.
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.
Schettini F, Fontana A, Gattazzo F, Strina C, Milani M, Cappelletti MR, Cervoni V, Morelli L, Curigliano G, Iebba V, Generali D. Schettini F, et al. Among authors: cervoni v. Eur J Cancer. 2023 Sep;191:112948. doi: 10.1016/j.ejca.2023.112948. Epub 2023 Jun 20. Eur J Cancer. 2023. PMID: 37454444 Free article.
Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Corona SP, et al. Among authors: cervoni v. Oncotarget. 2022 Dec 6;13:1307. doi: 10.18632/oncotarget.28317. Oncotarget. 2022. PMID: 36473136 Free PMC article. No abstract available.